SYNACT PHARMA ApS Financials, key figures and credit report
Gross profit -53 194.9 kDKK FY 2025 -102.5% vs 2024
EBIT -65 223.1 kDKK FY 2025 -81% vs 2024
Net debt -11 660.3 kDKK FY 2025 -32% vs 2024
Quick ratio 2.2 FY 2025 -0.5 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -43 429.98 | -46 951.48 | -63 448.35 | -26 274.87 | -53 194.92 |
| Employee benefit expenses | -2 647.44 | -7 454.00 | -6 409.70 | -8 310.37 | -10 140.95 |
| Total depreciation | - 472.09 | - 816.86 | -1 011.14 | -1 449.43 | -1 887.27 |
| EBIT | -46 549.51 | -55 222.33 | -70 869.19 | -36 034.67 | -65 223.14 |
| Other financial income | 0.08 | 221.84 | 53.61 | 166.39 | 61.84 |
| Other financial expenses | - 108.82 | - 279.81 | -93.34 | - 109.10 | - 151.64 |
| Pre-tax profit | -46 658.26 | -55 280.30 | -70 908.93 | -35 977.38 | -65 312.94 |
| Income taxes | 5 501.63 | 5 500.00 | 5 500.00 | 5 500.00 | 5 500.00 |
| Net earnings | -41 156.63 | -49 780.30 | -65 408.93 | -30 477.38 | -59 812.94 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Development expenditure | 3 090.18 | 4 626.17 | 6 291.49 | 7 856.95 | 9 215.98 |
| Intangible assets total | 3 090.18 | 4 626.17 | 6 291.49 | 7 856.95 | 9 215.98 |
| Tangible assets total | |||||
| Investments total | 199.49 | 180.31 | 93.49 | 93.49 | 93.49 |
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 11 616.60 | ||||
| Current owed by particip. interest comp. | 483.57 | 121.00 | |||
| Prepayments and accrued income | 203.31 | 46.02 | 67.06 | 11 522.02 | 2 005.31 |
| Current other receivables | 1 631.68 | 2 828.29 | 2 694.16 | 3 502.56 | 3 407.83 |
| Current deferred tax assets | 5 500.00 | 5 500.00 | 5 500.00 | 5 500.00 | 5 500.00 |
| Short term receivables total | 7 334.99 | 19 990.92 | 8 261.23 | 21 008.15 | 11 034.14 |
| Cash and bank deposits | 2 919.44 | 13 149.75 | 12 138.68 | 8 833.48 | 11 660.30 |
| Cash and cash equivalents | 2 919.44 | 13 149.75 | 12 138.68 | 8 833.48 | 11 660.30 |
| Balance sheet total (assets) | 13 544.10 | 37 947.15 | 26 784.89 | 37 792.08 | 32 003.91 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 1 000.00 | 1 000.00 | 1 000.00 | 1 000.00 | 1 000.00 |
| Share premium account | 17 060.00 | 17 060.00 | |||
| Asset revaluation reserve | 83 635.02 | 160 761.18 | |||
| Retained earnings | -53 889.36 | -95 045.99 | 79 994.89 | 54 585.96 | 79 108.59 |
| Profit of the financial year | -41 156.63 | -49 780.30 | -65 408.93 | -30 477.38 | -59 812.94 |
| Shareholders equity total | 6 649.03 | 33 994.89 | 15 585.96 | 25 108.59 | 20 295.65 |
| Provisions | 100.00 | 4 027.09 | 1 356.97 | 1 232.00 | |
| Non-current liabilities total | |||||
| Current trade creditors | 5 363.01 | 2 439.60 | 6 062.02 | 10 766.61 | 9 783.28 |
| Current owed to group member | 1.02 | ||||
| Other non-interest bearing current liabilities | 1 531.04 | 1 412.67 | 1 109.82 | 559.92 | 692.99 |
| Current liabilities total | 6 895.07 | 3 852.26 | 7 171.84 | 11 326.52 | 10 476.26 |
| Balance sheet total (liabilities) | 13 544.10 | 37 947.15 | 26 784.89 | 37 792.08 | 32 003.91 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated